Responses
Neuromuscular
Original research
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
Compose a Response to This Article
Other responses
No responses have been published for this article.